New approaches to investigate novel agents in Ewing sarcoma: A report from the Children's Oncology Group Bone Tumor Committee Review


Authors: Daley, J. D.; Whiteway, S. L.; Heske, C. M.; Dela Cruz, F. S.; Whittle, S. B.; Cohen-Gogo, S.; Collier, A. B.; Gupta, A.; Ohm, J.; Clark, A.; Soragni, A.; Lawlor, E.; Setty, B.; Grohar, P. J.; Janeway, K.; Reed, D. R.; Slotkin, E. K.; Bailey, K. M.
Review Title: New approaches to investigate novel agents in Ewing sarcoma: A report from the Children's Oncology Group Bone Tumor Committee
Abstract: Outcomes for relapsed Ewing sarcoma remain consistently poor. Continued efforts to consider creative new approaches for the treatment of relapsed Ewing sarcoma are needed. The Children's Oncology Group Bone Tumor Committee convened a New Strategies for Ewing Sarcoma Task Force to systematically evaluate agents for inclusion in future Phase II or III clinical trials for relapsed Ewing sarcoma. In addition, the Task Force summarized the possible limitations of common trial designs and considered new approaches to study promising agents in clinical trials. Here, we summarize this work and propose next steps for future trials for relapsed Ewing sarcoma. © 2025 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Keywords: relapse; ewing sarcoma; aya
Journal Title: Pediatric Blood and Cancer
ISSN: 1545-5009
Publisher: Wiley Periodicals, Inc  
Publication status: Online ahead of print
Date Published: 2025-07-24
Online Publication Date: 2025-07-24
Language: English
DOI: 10.1002/pbc.31917
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Emily Kanaya Slotkin
    66 Slotkin
  2. Damon Reed
    12 Reed